FBLN5
Fibulin-5
Also known as: ARMD3, DANCE, EVEC, FBLN5_HUMAN, UP50
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UBX5
- Gene
- FBLN5
- Ensembl
- ENSG00000140092
- Chromosome
- 14
- Canonical length
- 448 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Plasma membrane
- Secretome location
- Secreted to extracellular matrix
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene is a secreted, extracellular matrix protein containing an Arg-Gly-Asp (RGD) motif and calcium-binding EGF-like domains. It promotes adhesion of endothelial cells through interaction of integrins and the RGD motif. It is prominently expressed in developing arteries but less so in adult vessels. However, its expression is reinduced in balloon-injured vessels and atherosclerotic lesions, notably in intimal vascular smooth muscle cells and endothelial cells. Therefore, the protein encoded by this gene may play a role in vascular development and remodeling. Defects in this gene are a cause of autosomal dominant cutis laxa, autosomal recessive cutis laxa type I (CL type I), and age-related macular degeneration type 3 (ARMD3). [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
448 residues, UniProt reviewed canonical sequence.
>Q9UBX5|FBLN5
1 MPGIKRILTV TILALCLPSP GNAQAQCTNG FDLDRQSGQC LDIDECRTIP EACRGDMMCV
61 NQNGGYLCIP RTNPVYRGPY SNPYSTPYSG PYPAAAPPLS APNYPTISRP LICRFGYQMD
121 ESNQCVDVDE CATDSHQCNP TQICINTEGG YTCSCTDGYW LLEGQCLDID ECRYGYCQQL
181 CANVPGSYSC TCNPGFTLNE DGRSCQDVNE CATENPCVQT CVNTYGSFIC RCDPGYELEE
241 DGVHCSDMDE CSFSEFLCQH ECVNQPGTYF CSCPPGYILL DDNRSCQDIN ECEHRNHTCN
301 LQQTCYNLQG GFKCIDPIRC EEPYLRISDN RCMCPAENPG CRDQPFTILY RDMDVVSGRS
361 VPADIFQMQA TTRYPGAYYI FQIKSGNEGR EFYMRQTGPI SATLVMTRPI KGPREIQLDL
421 EMITVNTVIN FRGSSVIRLR IYVSQYPFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FBLN5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 668 nTPM
Expression across tissuesHPA
Tissue
- blood vessel: 668 nTPM
- heart muscle: 181 nTPM
- adipose tissue: 151 nTPM
- endometrium: 135 nTPM
- lung: 133 nTPM
- gallbladder: 119 nTPM
Single-cell type
- peritubular myoid cells: 856 nCPM
- leydig cells: 706 nCPM
- hepatic stellate cells: 465 nCPM
- fibroblasts: 322 nCPM
- fibro-adipogenic progenitors: 270 nCPM
- decidual stromal cells: 254 nCPM
Immune cell
- basophil: 6.7 nTPM
- neutrophil: 2.7 nTPM
- eosinophil: 2.4 nTPM
- naive CD8 T-cell: 1.5 nTPM
- gdT-cell: 0.8 nTPM
- naive CD4 T-cell: 0.7 nTPM
Brain region
- medulla oblongata: 27 nTPM
- choroid plexus: 27 nTPM
- spinal cord: 21 nTPM
- cerebral cortex: 20 nTPM
- basal ganglia: 18 nTPM
- thalamus: 17 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FBLN5.
Disease | AllUniProt
Conditions FBLN5 is implicated in, by any mechanism.
- Charcot-Marie-Tooth disease, demyelinating, type 1H (CMT1H) MIM:619764
- Cutis laxa, autosomal dominant, 2 (ADCL2) MIM:614434
- Cutis laxa, autosomal recessive, 1A (ARCL1A) MIM:219100
- Macular degeneration, age-related, 3 (ARMD3) MIM:608895
Disease | GeneticClinVar
8 pathogenic / likely-pathogenic of 688 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Charcot-Marie-Tooth disease, demyelinating, IIA 1H
- Cutis laxa, autosomal recessive, type 1A
- Cutis laxa, autosomal dominant 2
- Hereditary sensorimotor neuropathy with hyperelastic skin
- Macular degeneration, age-related, 3
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.17
- gnomAD pLI
- 1
- gnomAD missense Z
- 1.56
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell-matrix adhesion
- elastic fiber assembly
- negative regulation of angiogenesis
- negative regulation of transcription by RNA polymerase II
- positive regulation of osteoblast proliferation
- positive regulation of transcription by RNA polymerase II
- protein localization to cell surface
- regulation of removal of superoxide radicals
- secretion
- intramembranous bone growth
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- EGF-type aspartate/asparagine hydroxylation site
- EGF-like domain
- EGF-like calcium-binding domain
- Growth factor receptor cysteine-rich domain superfamily
- EGF-like calcium-binding, conserved site
- Complement Clr-like EGF domain
- NOTCH1, EGF-like calcium-binding domain
- Nephronectin domain-containing protein
- Fibulin, C-terminal Ig-like domain
- Calcium-binding EGF domain
- Complement Clr-like EGF-like
- Fibulin C-terminal Ig-like domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of FBLN5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FBLN5 as an antibody target. Whether an autoantibody or antibody against FBLN5 could matter depends on whether native FBLN5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FBLN5 is annotated as secreted, so native FBLN5 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label FBLN5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...